Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
10.13
-0.24 (-2.31%)
At close:
Mar 27, 2023, 4:00 PM
10.33
+0.20 (1.97%)
After-hours:
Mar 27, 2023, 6:51 PM EDT
Immuneering Market Cap
Immuneering has a market cap or net worth of $267.80 million as of March 28, 2023. Its market cap has increased by 45.14% in one year.
Market Cap
267.80M
Enterprise Value
167.11M
1-Year Change
45.14%
Ranking
Category
Stock Price
$10.13
Market Cap Chart
Since the IPO on July 30, 2021, Immuneering Corporation's market cap has decreased from $365.84M to $267.80M, a decrease of -26.80%. That is a compound annual growth rate of -17.23%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 24, 2023 | 267.80M | -2.23% |
| Mar 23, 2023 | 273.90M | 1.37% |
| Mar 22, 2023 | 270.20M | 16.89% |
| Mar 21, 2023 | 231.15M | 11.45% |
| Mar 20, 2023 | 207.40M | -2.60% |
| Mar 17, 2023 | 212.94M | 2.41% |
| Mar 16, 2023 | 207.93M | 1.42% |
| Mar 15, 2023 | 205.03M | -8.05% |
| Mar 14, 2023 | 222.97M | 5.63% |
| Mar 13, 2023 | 211.09M | 6.24% |
| Mar 10, 2023 | 198.69M | 5.46% |
| Mar 9, 2023 | 188.40M | 5.47% |
| Mar 8, 2023 | 178.64M | 22.87% |
| Mar 7, 2023 | 145.39M | 6.17% |
| Mar 6, 2023 | 136.95M | 1.96% |
| Mar 3, 2023 | 134.31M | 1.60% |
| Mar 2, 2023 | 132.20M | -1.76% |
| Mar 1, 2023 | 134.57M | 4.29% |
| Feb 28, 2023 | 129.03M | 1.88% |
| Feb 27, 2023 | 126.66M | 2.35% |
| Feb 24, 2023 | 123.75M | -11.01% |
| Feb 23, 2023 | 139.06M | 2.93% |
| Feb 22, 2023 | 135.10M | 9.17% |
| Feb 21, 2023 | 123.75M | 2.18% |
| Feb 17, 2023 | 121.12M | 6.00% |
View and export this data all the way back to 2021.
Start Free Trial.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| TELA Bio, Inc. | 189.10M |
| KORU Medical Systems, Inc. | 177.98M |
| Alaunos Therapeutics, Inc. | 125.65M |
| Champions Oncology, Inc. | 56.27M |
| Candel Therapeutics, Inc. | 47.82M |
| Taysha Gene Therapies, Inc. | 45.52M |
| NextCure, Inc. | 44.99M |
| Leap Therapeutics, Inc. | 33.17M |
| PolyPid Ltd. | 9.75M |